Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
October 16, 2024 09:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
CAR-T Cell Therapy Market Research 2024: Regulatory Approvals, Pricing, Reimbursement, Degree of Market Penetration, Mergers and Acquisitions, IPOs, and Financing Events
October 16, 2024 04:02 ET
|
Research and Markets
Dublin, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2024" report has been added to ResearchAndMarkets.com's offering. ...
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 04, 2024 09:00 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
September 03, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)
September 03, 2024 08:30 ET
|
Imugene Limited
Three complete responses in azer-cel allogeneic CD19 CAR T Phase 1b trial in blood cancer (Diffuse Large B-Cell Lymphoma)
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
August 26, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and
Provides Business Update
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 08, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Second Quarter 2024 Financial Results
and Business Updates
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
August 07, 2024 02:00 ET
|
Cellectis Inc.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Provides Financial Results for the Second Quarter 2024
August 06, 2024 16:30 ET
|
Cellectis Inc.
ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273...